Psychological Distress in Breast Cancer Patients During Oncological Inpatient Rehabilitation: Incidence, Triggering Factors and Correlation with Treatment-induced Side Effects
Overview
Affiliations
As a result of the cancer diagnosis and the mostly multimodal, stressful therapy, psychological distress is a common symptom in breast cancer patients. As part of this prospective study, 1400 patients who were admitted to the hospital for oncological rehabilitation were screened for distress and somatic, therapy-induced secondary disorders. Mean distress in the screened population was 5.6 ± 2.56 (range 0-10). In 942 cases (67.3%) a significant distress score (≥ 5) was detected and in 587 cases (41.9%) very high levels of distress (≥ 7) was observed. Psychological distress significantly correlated with younger age, presence of triple negative breast cancer (TNBC), tumor recurrence and metastasis, and inability to work. Treatment-induced side effects such as lymphedema, CIPN or extensive tumor resection (mastectomy) showed a (not significant) trend for higher distress. The high incidence of distress underscores the importance of psycho-oncological therapy offers and the great importance of occupational measures during oncological rehabilitation such as the importance of a successful return to work for a better quality of life in breast cancer patients.
Tang W, Mangantig E, Iskandar Y, Cheng S, Yusuf A, Jia K BMJ Open. 2024; 14(9):e077067.
PMID: 39327054 PMC: 11429273. DOI: 10.1136/bmjopen-2023-077067.
Returning to Work after Breast Cancer: A One-Year Mixed-Methods Study.
Magnavita N, Meraglia I, Terribile D Int J Environ Res Public Health. 2024; 21(8).
PMID: 39200667 PMC: 11353812. DOI: 10.3390/ijerph21081057.
Park J, Chun M, Bae S, Woo J, Chon E, Kim H Sci Rep. 2024; 14(1):15052.
PMID: 38956137 PMC: 11219858. DOI: 10.1038/s41598-024-65132-y.
Guo L, Hong S, Wang X, Wang S, Wang N, Wei X Breast Cancer (Dove Med Press). 2024; 16:289-303.
PMID: 38835647 PMC: 11149640. DOI: 10.2147/BCTT.S462296.
Wolff J, Seidel S, Wuelfing P, Lux M, Zu Eulenburg C, Smollich M Front Oncol. 2024; 14:1354377.
PMID: 38699636 PMC: 11064693. DOI: 10.3389/fonc.2024.1354377.